Introduction: We sought to determine the 30-Day Readmission rate (30-DRr) for patients with Type 2 Diabetes (T2DM) with coexisting Chronic Systolic Heart failure (cSHF) and Atrial Fibrillation (AF) , readmission rate mortality, & healthcare utilization in the United States.

Methods: Using the 2017-2018 National Readmission Database, we conducted a retrospective analysis of patient discharges with T2DM as a principal diagnosis and cSHF&AF as a secondary diagnosis. Readmission was defined as the first admission for any non-trauma diagnosis within 30 days of the index admission. The outcomes were 30DRr, readmission mortality rate & resource utilization defined by LOS, Average & Total patient charges/hospital costs.

Results: A total of 29,967 index hospitalization for T2DM with co-existing cSHF & AF; mean age was 71.4years, & 69.8% males. In-hospital mortality rate for index admission was 2.89%, while 30-DRr was 17.5% (Figure 1) . The In-hospital mortality rate was 6.78% among this group of readmitted patients, compared to index admission (6.78% vs. 2.89%, adjusted p=0.0001) . The total hospital days associated with readmission were 34,691 days, with a total hospital cost burden of $78,400,000 & a total economic burden on patients of $344,000,000.

Conclusion: T2DM with cSHF&AF had a high number of 30-DRr, associated with incremental mortality & high health care burden.


M.Fatuyi: n/a. L.Pereira: None. V.Sharma: None. L.Khokhlov: None. V.Namdarizandi: None. A.Zain elabidin: None. R.T.Orji: None. K.Shemisa: Speaker's Bureau; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, ESPERION Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at